Internal Medicine Alert – October 15, 2024
October 15, 2024
View Issues
-
Does Semaglutide Protect Against Adverse Effects from COVID-19?
Semaglutide recipients who developed COVID-19 had significant protection against the occurrence of adverse outcomes, including death.
-
Poor Diabetes Control Associated with Poorer Coronary Stent Outcomes
In this large, observational study of diabetic patients with coronary stents, poorer glycemic control as measured by hemoglobin A1c was associated with stepwise hazard for stent failure over a period of more than six years, primarily driven by in-stent restenosis.
-
Clarifying the Risk of Aortic Aneurysm Development
A large, cross-sectional study of adults by aortic computed tomography angiography has shown that aortic aneurysms (AAs) are more frequent in men than women. While increasing age and body surface area were common risk factors for AA, hypertension was associated with thoracic AA, and hypercholesterolemia and smoking were risk factors for abdominal AA.
-
A Review of HIV Pre-Exposure Prophylaxis
Human immunodeficiency virus (HIV) pre-exposure prophylaxis is a tool for preventing HIV, especially among high-risk populations. Three medication options are available. Regular screening for HIV and sexually transmitted infections is required, and adherence is crucial for effectiveness. PrEP is underused but increasingly covered by insurance, offering an important preventive option in sexual healthcare.
-
Nalmefene Injection (Zurnal) and Intranasal Nalmefene HCl (Opvee)
The U.S. Food and Drug Administration has approved the first nalmefene autoinjector for the emergency treatment of known or suspected opioid overdose. Nalmefene is an opioid antagonist and an analog of naltrexone. It was granted a priority review and accelerated approval with a breakthrough therapy designation. It is distributed by Purdue Pharma L.P. as Zurnal.
-
An ECG in Disguise?
How would you interpret the two-lead rhythm strip shown in the figure? Hint: Is there a pattern?